Pfizer

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Pfizer and other ETFs, options, and stocks.

About PFE

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. 

CEO
Albert Bourla
CEOAlbert Bourla
Employees
88,000
Employees88,000
Headquarters
New York, New York
HeadquartersNew York, New York
Founded
1849
Founded1849
Employees
88,000
Employees88,000

PFE Key Statistics

Market cap
148.28B
Market cap148.28B
Price-Earnings ratio
34.48
Price-Earnings ratio34.48
Dividend yield
6.51%
Dividend yield6.51%
Average volume
58.14M
Average volume58.14M
High today
$26.45
High today$26.45
Low today
$25.70
Low today$25.70
Open price
$25.80
Open price$25.80
Volume
57.66M
Volume57.66M
52 Week high
$31.54
52 Week high$31.54
52 Week low
$24.48
52 Week low$24.48

PFE News

Seeking Alpha 2d
Pfizer meets amyloidosis rival as BridgeBio wins FDA nod for Attruby

The U.S. FDA late Friday approved BridgeBio Pharma’s (NASDAQ:BBIO) lead asset Attruby for the rare heart disorder transthyretin cardiac amyloidosisin in a poten...

Pfizer meets amyloidosis rival as BridgeBio wins FDA nod for Attruby
Benzinga 3d
Pfizer Stock Drops 10% In November On News Of Kennedy's HHS Nomination

Pfizer Inc PFE shares are trading lower by 10% to $25.13 in November and are near decade-lows after President-elect Donald Trump last week announced his intenti...

Pfizer Stock Drops 10% In November On News Of Kennedy's HHS Nomination
TipRanks 5d
Zai Lab, Pfizer enter collaboration for Xacduro

Zai Lab (ZLAB) and Pfizer (PFE) announced a strategic collaboration for the novel antibacterial drug Xacduro in mainland China. Pfizer’s affiliated companies wi...

Analyst ratings

54%

of 26 ratings
Buy
42.3%
Hold
53.8%
Sell
3.8%

More PFE News

TipRanks 5d
Leerink views Chris Boshoff as ‘strong choice’ for Pfizer’s CSO

Leerink notes Pfizer (PFE) announced that Chris Boshoff will become the new Chief Scientific Officer, succeeding Mikael Dolsten. The firm views Boshoff as a str...

TipRanks 5d
Pfizer Appoints Company Insider Chris Boshoff as New Head of R&D

Pharmaceutical giant Pfizer (PFE) has appointed company insider Chris Boshoff its new chief of research and development (R&D) as it scrambles to produce new med...

Seeking Alpha 5d
Pfizer names head of oncology as new R&D chief

Pfizer (NYSE:PFE) on Wednesday promoted Chris Boshoff, the executive in charge of its oncology business, as the company's new chief scientific officer, a role r...

Pfizer names head of oncology as new R&D chief
TipRanks 5d
Pfizer confirms Chris Boshoff as chief scientific officer

Pfizer (PFE) announced that after a comprehensive internal and external selection process, the company is appointing Chris Boshoff, M.D., PhD, as Chief Scientif...

TipRanks 6d
Pfizer announces EC approval for Hympavzi

Pfizer (PFE) announced that the European Commission, or EC, has granted marketing authorization for Hympavzi for the routine prophylaxis of bleeding episodes in...

Benzinga 6d
BridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa In Lucrative But Competitive ATTR-CM Market

On Monday, BridgeBio Pharma, Inc. BBIO presented initial outcomes from the ATTRibute-CM open-label extension (OLE) study of acoramidis in ATTR-CM at the America...

BridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa In Lucrative But Competitive ATTR-CM Market
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.